Non-Hodgkin lymphoma epidemiology and demographics
|
Non-Hodgkin lymphoma Microchapters |
|
Differentiating Non-Hodgkin's Lymphoma |
|---|
|
Treatment |
|
Case Studies |
|
Non-Hodgkin lymphoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Non-Hodgkin lymphoma epidemiology and demographics |
|
Non-Hodgkin lymphoma epidemiology and demographics in the news |
|
Risk calculators and risk factors for Non-Hodgkin lymphoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2], Sowminya Arikapudi, M.B,B.S. [3]
Overview
Non-Hodgkin lymphoma (NHL) accounts for about 4% of all cancers in the United States. American cancer society statistic center estimates the incidence of non Hodgkin's lymphoma as 74680 in the year 2018, the incidence rate was estimated to 19 in 100,000 individuals in the years 2010-2014. The age-adjusted prevalence of non-Hodgkin lymphoma is 131.1 per 100,000 individuals in 2011.
Epidemiology and Demographics
Prevalence
- In the United States, the age-adjusted prevalence of non-Hodgkin lymphoma is 131.1 per 100,000 individuals in 2011.[1]
Incidence
- In the year 2018 the incidence of non-Hodgkin lymphoma was estimated to be 74680.
- Between 2010-2014, the incidence of non-Hodgkin lymphoma was estimated to be 19 cases per 100,000 individuals in the United States.[2][3]
- The delay-adjusted incidence of non-Hodgkin lymphoma in 2011 was estimated to be 20.2 per 100,000 individuals in the United States.
- In 2011, the age-adjusted incidence of non-Hodgkin lymphoma was 19.63 per 100,000 individuals in the United States.[1][4]
Age
- While the overall age-adjusted incidence of non-Hodgkin lymphoma in the United States between 2007 and 2011 is 19.7 per 100,000 individuals, the age-adjusted incidence of non-Hodgkin lymphoma by age category is:[5]
- Under 65 years: 9.3 per 100,000
- 65 and over: 91.5 per 100,000
- Shown below is an image depicting the incidence of non-Hodgkin lymphoma by the age of diagnosis in males in the United States between 1975 and 1977 as well as between 2009 and 2011.[5]
Gender
- Males are more commonly affected with non-Hodgkin lymphoma than females
- In the United States, the age-adjusted prevalence of non-Hodgkin lymphoma by gender in 2011 is:[5]
- In males: 150.4 %
- In females: 114.3 %
- In the United States, the delay-adjusted incidence of non-Hodgkin lymphoma by gender in 2011 is:[5]
- In males: 24.77 per 100,000 individuals
- In females: 16.58 per 100,000 individuals
- In the United States, the age-adjusted incidence of non-Hodgkin lymphoma by gender on 2011 is:[5]
- In males: 24.07 per 100,000 individuals
- In females: 16.11 per 100,000 individuals
- Shown below is an image depicting the delay-adjusted incidence and observed incidence of non-Hodgkin lymphoma by gender and race in the United States between 1975 and 2011. These graphs are adapted from SEER: The Surveillance, Epidemiology, and End Results Program of the National Cancer Institute.[5]
Race
- Shown below is a table depicting the age-adjusted prevalence of non-Hodgkin lymphoma by race in 2011 in the United States.[1]
| All Races | White | Black | Asian/Pacific Islander | Hispanic | |
| Age-adjusted prevalence | 131.1 per 100,000 | 141.2 per 100,000 | 95.3 per 100,000 | 83.5 per 100,000 | 101.4 per 100,000 |
- Shown below is an image depicting the incidence of non-Hodgkin lymphoma by race in the United States between 1975 and 2011.[5]
API: Asian/Pacific Islander; AI/AN: American Indian/ Alaska Native
References
- ↑ 1.0 1.1 1.2 Chiu BC, Hou N (2015). "Epidemiology and etiology of non-hodgkin lymphoma". Cancer Treat. Res. 165: 1–25. doi:10.1007/978-3-319-13150-4_1. PMID 25655604.
- ↑ "American Cancer Society | Cancer Facts & Statistics".
- ↑ Adult Non-Hodgkin Lymphoma Treatment. National Cancer Institute. http://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq Accessed on October 1, 2015
- ↑ Chihara D, Nastoupil LJ, Williams JN, Lee P, Koff JL, Flowers CR (May 2015). "New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy". Expert Rev Anticancer Ther. 15 (5): 531–44. doi:10.1586/14737140.2015.1023712. PMC 4698971. PMID 25864967.
- ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.